Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Rocket Pharmaceuticals, Inc. - Common Stock (NQ:RCKT)

6.330 +0.180 (+2.93%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,203,157
Open 6.130
Bid (Size) 6.230 (4)
Ask (Size) 6.400 (21)
Prev. Close 6.150
Today's Range 6.090 - 6.390
52wk Range 4.550 - 26.98
Shares Outstanding 65,837,894
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Stocks Insiders Are Buying Rapidly Amid Market Volatility
Despite market volatility, these stocks are seeing strong buys by insiders. 
Via Talk Markets
Topics Stocks / Equities
Netflix, Ericsson, Hewlett Packard Enterprise And Other Big Stocks Moving Higher On Monday
Via Benzinga

Performance

YTD
-50.2%
-50.2%
1 Month
-23.9%
-23.9%
3 Month
-37.7%
-37.7%
6 Month
-64.1%
-64.1%
1 Year
-72.2%
-72.2%

More News

Read More
Rocket Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Top 3 Health Care Stocks That Could Blast Off This Month
Via Benzinga
Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Rocket Pharmaceuticals, Inc
Via Business Wire
Rocket Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock
From Rocket Pharmaceuticals, Inc.
Via Business Wire
3 Small-Cap Stocks That Are Ready to Rocket Higher
Via MarketBeat
Topics Government
Exposures Political
Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: Analyst
Via Benzinga
Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Association’s 2024 Late-Breaking Science Sessions
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday
Via Benzinga
RCKT Stock Earnings: Rocket Pharmaceuticals Misses EPS for Q2 2024
Via InvestorPlace
Rocket Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Progress
From Rocket Pharmaceuticals, Inc.
Via Business Wire
FDA Rejects Rocket Pharmaceuticals' Gene Therapy For Rare Immune Disorder, Asks For More Data, Stock Slides
Via Benzinga
Exposures Product Safety
Nike, Accolade And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Rocket Pharmaceuticals Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel)
From Rocket Pharmaceuticals, Inc.
Via Business Wire
These 3 Clinical-Stage Biotech Stocks Can Offer Exponential Gains
Via Talk Markets

Frequently Asked Questions

Is Rocket Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Rocket Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Rocket Pharmaceuticals, Inc. - Common Stock trade on?
Rocket Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Rocket Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Rocket Pharmaceuticals, Inc. - Common Stock is RCKT on the Nasdaq Stock Market
What is the current price of Rocket Pharmaceuticals, Inc. - Common Stock?
The current price of Rocket Pharmaceuticals, Inc. - Common Stock is 6.330
When was Rocket Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Rocket Pharmaceuticals, Inc. - Common Stock was at 04/17/25 04:00 PM ET
What is the market capitalization of Rocket Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Rocket Pharmaceuticals, Inc. - Common Stock is 416.75M
How many shares of Rocket Pharmaceuticals, Inc. - Common Stock are outstanding?
Rocket Pharmaceuticals, Inc. - Common Stock has 417M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.